Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4917838 adjunctive placebo-controlled phase III study in schizophrenia
2010-020696-23Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing RO4917838 adjunct to antipsychotics with Placebo adjunct to antipsychotics (2 arms). Primary endpoint: PANSS positive symptom factor score. Started Oct 2010; status: terminated.
02
Drugs
bitopertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-020696-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020696-23.